Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform (EOP) Clinical Trial NEW HAVEN, Conn. and SAN FRANCISCO, May 2, 2023 /PRNewswire/ — Arvinas, Inc. (Nasdaq: ARVN) and...
BrightInsight Ranked 217th Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™ 701% revenue growth underscores BrightInsight’s position as the de facto digital health platform for the world’s top biopharma and medtech companies...
CLEERLY TAKES PRECISION HEART CARE TO THE NEXT LEVEL WITH CLEERLY 2.2.0Cleerly 2.2.0 includes UX updates and three high-value tools to better evaluate heart disease NEW YORK, February 8, 2022 — Cleerly, the company creating a new standard of care for heart...
Sierra Oncology Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis —New Drug Application submission planned for second quarter of 2022— —Full data set to be presented at...
Sierra Oncology Announces Pricing of Upsized Public Offering of Securities SAN MATEO, Calif.–(BUSINESS WIRE)– Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today...
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471 – Collaboration combines Arvinas’ investigational estrogen receptor-targeting breast cancer therapy with Pfizer’s deep experience in breast oncology...
Recent Comments